Newsroom - Page 6

Posters focus on next-generation sequencing ovarian cancer and identify candidates for treatment with PARP inhibitors.
Healthcare groups and members of the Senate Judiciary Committee have weighed in with concerns about decreased competition and harm to consumers if the Aetna-Humana and Anthem-Cigna transactions are approved.
Peter S. Amenta, MD, PhD, spent 8 years as the dean of Rutgers Robert Wood Johnson Medical School during a period of tremendous growth and change.
The trial, conducted in France, was a proof-of-concept study to evaluate the efficacy of targeted agents in patients, based on their tumor's molecular profile.
Innovative trials offer the promise that patients can be treated in their own communities instead of traveling to faraway cancer centers.
Telehealth follow up consultations after a surgical operation have become preferred compared to in-person visits, according to 2 recent studies.
In a letter to Pathway Genomics, the FDA has expressed interest in discussing the company's validation strategy as well as evaluating data on clinical sensitivity and specificity of the CancerIntercept Detect test.
The problem in Kansas is the same as other states without Medicaid expansion: the ACA envisioned universal coverage, and funds to treat the uninsured are dwindling because it was expected that patients who are now in a "gap" would have insurance.
Diabetes Compendium
Oncology Compendium